Drugs A-Z Is my price fair? Price changes Drug markups Drug shortages Recalls Medicare prices Upcoming generics What people paid Guides Share what you paid
Theme

Updated daily

Drug recalls

Every FDA drug recall since 2004 - 18,109 enforcement reports, newest first, with what was recalled, why, the lots and the company. Class I is the most serious.

Class IITerminatedMay 15, 2019Carvedilol TabletsLabeling; Label Mix-up; report received of one bottle labeled as Acyclovir Tablets USP 400 mg actually contained Carvedilol Tablets 6.25 mgZydus Pharmaceuticals USA Inc · D-1273-2019Class IITerminatedMay 15, 2019Acyclovir TabletsLabeling; Label Mix-up; report received of one bottle labeled as Acyclovir Tablets USP 400 mg actually contained Carvedilol Tablets 6.25 mgZydus Pharmaceuticals USA Inc · D-1272-2019Class IIITerminatedMay 8, 2019Dermoplast Anesthetic PAIN & ITCHLabeling: Not Elsewhere Classified: Full cases may contain canisters that incorrectly state the net weight is 2.75 oz. rather than the correct net weight of 2.0 oz.Advantice Health · D-1280-2019Class IIITerminatedMay 8, 2019Dermoplast Anesthetic PAIN & ITCHLabeling: Not Elsewhere Classified: canisters incorrectly state the net weight is 2.75 oz. rather than the correct net weight of 2.0 oz.Advantice Health · D-1279-2019Class IITerminatedMay 8, 2019GlipiZIDE Extended-release TabletsFailed Dissolution Specifications: dissolution failure at time zero of the repackaged lot. Drug release results were slightly above specification at time zero.American Health Packaging · D-1276-2019Class IITerminatedMay 8, 2019RevontoPresence of Precipitate: Appearance is Out of Specification for the reconstituted solution during 24-month stability time point analysis.US Worldmeds LLC · D-1275-2019Class IITerminatedMay 8, 2019BEVACIZUMAB 1.25 mg/0.05 mL 31G MJ syringe Intravitreal Injection. This biologic product was repackaged by...Defective Delivery System: difficult to expressPacifico National, Inc. dba AmEx Pharmacy · D-1271-2019Class IITerminatedMay 8, 2019Losartan Potassium/HCTZCGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level of...RemedyRepack Inc. · D-1270-2019Class IIOngoingMay 8, 2019Losartan Potassium and Hydrochlorothiazide TabletsCGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level.Torrent Pharma Inc. · D-1269-2019Class IIOngoingMay 8, 2019Losartan Potassium and Hydrochlorothiazide TabletsCGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level.Torrent Pharma Inc. · D-1268-2019Class IIOngoingMay 8, 2019Losartan Potassium and Hydrochlorothiazide TabletsCGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level.Torrent Pharma Inc. · D-1267-2019Class IIOngoingMay 8, 2019Losartan Potassium TabletsCGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level.Torrent Pharma Inc. · D-1266-2019Class IIOngoingMay 8, 2019Losartan Potassium TabletsCGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level.Torrent Pharma Inc. · D-1265-2019Class IIOngoingMay 8, 2019Losartan Potassium TabletsCGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level.Torrent Pharma Inc. · D-1264-2019Class IIOngoingMay 8, 2019Losartan Potassium TabletsCGMP Deviations: Detection of trace amounts of N-Methylnitrosobutyric acid (NMBA) impurity found in the Active Pharmaceutical Ingredient (API)Legacy Pharmaceutical Packaging LLC · D-1263-2019Class IITerminatedMay 8, 2019TriMix MEDIUMLack of assurance of sterility for injectables and solutions intended to be sterile.Customceutical Compounding · D-1262-2019Class IITerminatedMay 8, 2019Trimix HIGHLack of assurance of sterility for injectables and solutions intended to be sterile.Customceutical Compounding · D-1261-2019Class IITerminatedMay 8, 2019Test PROCYPLack of assurance of sterility for injectables and solutions intended to be sterile.Customceutical Compounding · D-1260-2019Class IITerminatedMay 8, 2019Test D (TESTOSTERONE CYPIONATE 200MG/ML VITAMIN D3 5Lack of assurance of sterility for injectables and solutions intended to be sterile.Customceutical Compounding · D-1259-2019Class IITerminatedMay 8, 2019Test D (TESTOSTERONE CYPIONATE 200MG/ML VITAMIN D3 5Lack of assurance of sterility for injectables and solutions intended to be sterile.Customceutical Compounding · D-1258-2019Class IITerminatedMay 8, 2019LipoplexLack of assurance of sterility for injectables and solutions intended to be sterile.Customceutical Compounding · D-1257-2019Class IITerminatedMay 8, 2019HCG (CHORIONIC GONADOTROPIN 1000 IU/ML PEP 25 mg/mL) inj 5 mL multidose vial compounded. Customceutical...Lack of assurance of sterility for injectables and solutions intended to be sterile.Customceutical Compounding · D-1256-2019Class IITerminatedMay 8, 2019Glutathione 200mg/mL inj. a) 10 ML and b) 12 ML MULTIDOSE VIAL MDV Compounded. Customceutical Compounding...Lack of assurance of sterility for injectables and solutions intended to be sterile.Customceutical Compounding · D-1255-2019Class IITerminatedMay 8, 2019BPlex (METHYLCOBALAMIN 1000 MCG/ML PYRIDOXAL 5 PHOSPHATE 20MG/ML DEXPANTHENOL 250MG/ML)Lack of assurance of sterility for injectables and solutions intended to be sterile.Customceutical Compounding · D-1254-2019Class IITerminatedMay 8, 2019BPlex (METHYLCOBALAMIN 1000 MCG/ML PYRIDOXAL 5 PHOSPHATE 20MG/ML DEXPANTHENOL 250MG/ML)Lack of assurance of sterility for injectables and solutions intended to be sterile.Customceutical Compounding · D-1253-2019Class IITerminatedMay 8, 2019HYDROmorphone 20 mg/100 mL Injectable SolutionSub-potencyAdvanced Pharma Inc. · D-1251-2019Class IIOngoingMay 8, 2019Losartan Potassium Tablets USP 25 mg 50 tabletsCGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level of...AVKARE Inc. · D-1250-2019Class IIOngoingMay 8, 2019Losartan Potassium Tablets USP 50 mg 50 tabletsCGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level of...AVKARE Inc. · D-1249-2019Class IIITerminatedMay 1, 2019Morphine Sulfate Extended-Release TabletsFailed Impurities/Degradation SpecificationsLupin Somerset · D-1247-2019Class IIITerminatedMay 1, 2019Morphine Sulfate Extended-Release TabletsFailed Impurities/Degradation SpecificationsLupin Somerset · D-1246-2019Class IIITerminatedMay 1, 2019Morphine Sulfate Extended-Release TabletsFailed Impurities/Degradation SpecificationsLupin Somerset · D-1245-2019Class IIITerminatedMay 1, 2019Morphine Sulfate Extended-Release TabletsFailed Impurities/Degradation SpecificationsLupin Somerset · D-1244-2019Class IIITerminatedMay 1, 2019Morphine Sulfate Extended-Release TabletsFailed Impurities/Degradation SpecificationsLupin Somerset · D-1243-2019Class IIITerminatedMay 1, 2019Carvedilol TabletsPresence of Foreign Tablets/Capsules: Customer complaint for a small, solid, light yellow substance, identified as a fragmented tablet of another drug product, found...Zydus Pharmaceuticals USA Inc · D-1242-2019Class IIITerminatedMay 1, 2019Fentanyl Citrate InjectionFailed impurities/degradation specification: Out of Specification result for total impurity at 4.0% (Limit: NMT 3.0%) at 12 months stability testing.Akorn Inc · D-1241-2019Class IITerminatedMay 1, 2019DelNido CardioplegiaLack of sterility assurance.CMC Enterprise Pharmacy · D-1240-2019Class IITerminatedMay 1, 2019Vancomycin 2000 mg in 0.9% Sodium Chloride 500 mL bagLack of sterility assurance.CMC Enterprise Pharmacy · D-1239-2019Class IITerminatedMay 1, 2019Vancomycin 1750 mg in 0.9% Sodium Chloride 500 mL bagLack of sterility assurance.CMC Enterprise Pharmacy · D-1238-2019Class IITerminatedMay 1, 2019Vancomycin 1500 mg in NS 250 mL bagLack of sterility assurance.CMC Enterprise Pharmacy · D-1237-2019Class IITerminatedMay 1, 2019Vancomycin 1250 mg in NS 250 mL bagLack of sterility assurance.CMC Enterprise Pharmacy · D-1236-2019

Help the next person

Know what your pharmacy pays.

Every price you share shows someone else what's fair - and which pharmacies charge the least. It takes 30 seconds and it's anonymous.